Navigation Links
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis

- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting -

CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc. (PDL) announced today that the ongoing CHOICE trial, a Phase 2, randomized, double-blind, placebo-controlled trial of daclizumab, met its primary endpoint in relapsing multiple sclerosis (MS) patients being treated with interferon beta. Patients receiving daclizumab 2 mg/kg subcutaneously every 2 weeks showed a significant reduction in the number of new or enlarged gadolinium-contrast-enhancing lesions (Gd-CELs) at week 24.

Daclizumab is a humanized monoclonal antibody that targets the IL-2 receptor on activated T cells. Study results will be submitted for presentation at an upcoming medical meeting later this year. Based on a joint review of the 24-week data, the companies plan to initiate a Phase 2 monotherapy trial of daclizumab, and to advance the overall clinical development program in relapsing MS.

"We are very pleased to see positive results from the first randomized trial of daclizumab in patients with relapsing MS, and we look forward to advancing the clinical development program with our partner and acknowledged leader in the MS field, Biogen Idec," said Mark A. McCamish, M.D., Ph.D., chief medical officer, PDL BioPharma. "While the week 24 data set will be presented later this year, we are planning to move forward with additional development activities, most notably the initiation of the SELECT trial, which will study daclizumab as a single agent in patients with relapsing MS."

"We congratulate PDL on conducting a successful trial of daclizumab in MS," said Al Sandrock, M.D., Ph.D., senior vice president, neurology research and development, Biogen Idec. "Daclizumab represents an exciti
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
5. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
6. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
9. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
Post Your Comments:
(Date:10/22/2014)... Oct 22, 2014 Antigen Discovery Inc. (ADi), ... , announced the receipt of a National Institutes ... (SBIR) from the National Institute of Dental and Craniofacial Research ... of a Pan-HIV Protein Microarray Chip, which will contain ... subtypes and aid in the development of safe and ...
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ga., June 13, 2011 Friends of Disabled Adults and ... IVC ), providing immediate aid shipments of equipment and supplies ... center of Joplin on May 22, 2011, leaving much of ... was able to send the first supply shipment to Joplin ...
... 2011 Chicago based Share Your Soles marked its twelfth ... celebration for Mona Purdy, Founder of Share Your Soles, but ... to those in need in just over a decade. ... events that provide the necessary support to putting shoes on ...
Cached Medicine Technology:Friends of Disabled Adults and Children Partners With Invacare to Provide Aid in Wake of Joplin Tornado 2Friends of Disabled Adults and Children Partners With Invacare to Provide Aid in Wake of Joplin Tornado 3Chicago Based Share Your Soles Expanding to Become Global Shoe Donation Leader 2
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... 2014 Mesothelioma researchers are reporting extended ... pemetrexed (Alimta), after his combination drug therapy became too ... , just posted on the Surviving Mesothelioma website. ... Center in Japan suggests that “maintenance therapy” with pemetrexed ... who cannot tolerate higher doses of cisplatin. , ...
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... DC, August 31, 2007 As schools reopen around the country, ... attention to alcohol prevention starting as early as fourth grade. ... last 15 years shows that among typical 4th graders, 10% ... 7% have had a drink in the past year. While ...
... a,memorandum to editorial writers and columnists:, FROM: ... SUBJECT: Katrina Storm Warning, On the second ... the Gulf Coast are struggling to rebuild their ... U.S. history. Disaster often strikes suddenly,and with too ...
... behind the increase, , , THURSDAY, Aug. 30 (HealthDay News) ... early -- playing year-round, joining competitive club or travel ... they,ll put themselves on the fast track to college ... But for too many of these kids, that fast ...
... its two Presidential Assassins off display, to attend ... 19., PHILADELPHIA, Aug. 30 The Mutter Museum ... remains of two,of the nation,s presidential assassins from its ... Assassins, Wednesday, September 19. A,portion of the brain of ...
... Karlin,Chairman and CEO of CRC HEALTH GROUP, the ... the acquisition of Bayside Marin,Recovery Center (684 Pt ... Located in Marin County, California, Bayside Marin is ... facility has an exceptional,reputation and provides a holistic ...
... RICHMOND, Va., Aug. 30 While nearly 4,000,Hispanics ... donation in,2006, strongly held myths regarding donation continue to ... and tissue donors. In,recognition of Hispanic Heritage Month, Donate ... community, long celebrated for its,zest for life, to get ...
Cached Medicine News:Health News:Underage drinking starts before adolescence 2Health News:Underage drinking starts before adolescence 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 4Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 5Health News:More Kids Are Suffering Sports Injuries 2Health News:More Kids Are Suffering Sports Injuries 3Health News:The Mutter Assassins Go to the Theater! 2Health News:The Mutter Assassins Go to the Theater! 3Health News:CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael 2Health News:Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: